PHIA Koninklijke Philips N.V.

Latest release of Philips Capsule Surveillance receives FDA clearance

Latest release of Philips Capsule Surveillance receives FDA clearance

March 15, 2022

  • Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
  • Facilitates remote patient oversight at mobile, eICU and virtual care clinical touchpoints
  • New FDA clearance covers additional use cases and information access methods

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today at that the latest solution has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA), paving the way for widespread deployment across healthcare systems in the USA.

Capable of utilizing streaming data from virtually any connected medical device, the solution aggregates patient data, analyses it to generate actionable insights and alerts, and sends timely notifications to the patient’s caregivers so that they can intervene before deterioration progresses further. This latest release of Philips Capsule Surveillance includes expanded interoperability into hospitals’ existing mobile clinical communication and collaboration tools and electronic intensive care units (eICUs) and virtual care population health management systems, offering more visibility on live streaming data, waveforms, device alarms and contextual alerts.

“This FDA clearance of the latest release of clinical surveillance solution enables more integrated viewing options within EMR and HIT tools through the secure web-based user interface.  The updated intended use provides flexible deployment configurations that Philips Capsule can offer to hospitals and health systems in the USA,” said Elad Benjamin, general manager of Clinical Data Services at Philips. “Properly implemented clinical surveillance has the potential to significantly improve patient outcomes by helping to avoid deterioration, while also improving the care team experience via clinical decision support and minimizing the burden of false and clinically unactionable alarms.”

Enhanced data visibility at eICU and virtual care locations

Philips Capsule Surveillance offers an enterprise-wide solution that complements eICU telehealth command center solutions, such as Philips eCareManager, by bringing together live-streaming patient data across multiple acuity settings, equipment brands and device types to show each patient’s immediate status. 

Smart rule clinical decision support

Built on the vendor-neutral Philips Capsule , which captures and normalizes streaming data from a network of connected devices, the Philips Capsule Surveillance software continuously analyzes patient data using patented technology to identify deteriorating conditions and critical events. The software applies a set of smart rules based on clinical parameters and current best-practice guidelines that can be tailored to an individual hospital’s protocols for specific morbidities.

Philips Capsule Surveillance allows clinicians to see patient data and patient monitor settings and alarms from multiple device types without needing to enter the patient’s room. When caring for infectious patients, this can help reduce the risk to clinical staff. Early identification of deteriorating patient conditions can also help to avoid complications and escalations, contributing to lower cost of care, while the ability to remotely monitor large numbers of patients and focus resources where needed can help mitigate the shortage of experienced clinicians.

The latest version of Philips Capsule Surveillance will be released in Q2 to limited sites in the USA. For more information, visit .

For more information on Philips’ full portfolio of connected care solutions being showcased in booth #2501 at the HIMSS22 Global Health Conference & Exhibition, please visit and follow  for #HIMSS22 updates throughout the event.

For further information, please contact:

Meredith Amoroso

Philips Global Press Office

Mobile:

E-mail:   

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment



EN
15/03/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

Marc Hesselink ... (+2)
  • Marc Hesselink
  • CFA

Philips/Execution is key/HOLD

Philips reported a better-than-expected 4Q25 update and a supportive CMD message. We increase our estimates, raise our target price from €23 to €26 and reiterate our Hold rating. Philips appears positioned to continue progressing operationally, but we believe consistent delivery will be required before we see meaningful outperformance versus the sector. Valuation at 15x adj EPS 2027F is in line with peers.

 PRESS RELEASE

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for spe...

Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real timeWith the largest-in-class 85 cm bore, Rembra accommodates challenging patient types, providing more access for complex interventions, bariatric imaging a...

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch